Biotech ETFs can help investors capitalize on health care innovation while avoiding the boom-or-bust nature of individual ...

From broad domestic exposure to global pharma and biotech, these funds cover the healthcare sector's main themes.

Designed to provide broad exposure to the Healthcare - Biotech segment of the equity market, the VanEck Biotech ETF (BBH) is a passively managed exchange traded fund launched on December 20, 2011.

Fri, April 3, 2026 at 2:17 PM UTC The biotech industry has been a robust roller-coaster over the last half decade. The State Street SPDR S&P Biotech ETF (NYSE: XBI), which tracks the biotech portion ...

The State Street SPDR S&P Biotech ETF (XBI) was launched on January 31, 2006, and is a passively managed exchange traded fund designed to offer broad exposure to the Healthcare - Biotech segment of ...

BBP specializes in pure biotechnology companies that have a marketable product. The fund stands to see significant capital gains from the acquisition of companies in its portfolio. A new ETF, BBP is ...

The Fidelity MSCI Health Care Index ETF (NYSEARCA:FHLC) is down about 5% year to date while the S&P 500 is up 7%. Over five ...

State Street SPDR S&P Biotech ETF (XBI) gained +40.32% over the past year and equally weights roughly 145 stocks to provide exposure to smaller biotech companies. iShares Biotechnology ETF (IBB) ...

As anyone in the biotech investing space can tell you, picking winners in this corner of the healthcare market can be extremely difficult. Failed trials, FDA concerns, and pricing issues have hit a ...